Ident. | Authors (with country if any) | Title |
---|
000087 (2014) |
Santiago Perez-Lloret [France] ; María Ver Nica Rey [France] ; James Crispo [Canada] ; Daniel Krewski [Canada] ; Marise Lapeyre-Mestre [France] ; Jean-Louis Montastruc [France] ; Olivier Rascol [France] | Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients |
000144 (2012) |
Maria C. Rodriguez-Oroz [Espagne] ; Elena Moro [Canada] ; Paul Krack [France] | Long-Term Outcomes of Surgical Therapies for Parkinson's Disease |
000156 (2011) |
Klaus Seppi [Autriche, Portugal] ; Daniel Weintraub [États-Unis] ; Miguel Coelho [Portugal] ; Santiago Perez-Lloret [France] ; Susan H. Fox [Canada] ; Regina Katzenschlager [Autriche] ; Eva-Maria Hametner [Autriche] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Christopher G. Goetz [États-Unis] ; Cristina Sampaio [Portugal] | The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease |
000157 (2011) |
Susan H. Fox [Canada] ; Regina Katzenschlager [Autriche] ; Shen-Yang Lim [Malaisie] ; Bernard Ravina [États-Unis] ; Klaus Seppi [Autriche] ; Miguel Coelho [Portugal] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Christopher G. Goetz [États-Unis] ; Cristina Sampaio [Portugal] | The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease |
000163 (2011) |
Olivier Rascol [France] ; Andres Lozano [Canada] ; Matthew Stern [États-Unis] ; Werner Poewe [Autriche] | Milestones in Parkinson's disease therapeutics |
000189 (2010) |
Fabrizio Stocchi [Italie] ; Olivier Rascol [France] ; Karl Kieburtz [États-Unis] ; Werner Poewe [Autriche] ; Joseph Jankovic [États-Unis] ; Eduardo Tolosa [Espagne] ; Paulo Barone [Italie] ; Anthony E. Lang [Canada] ; C. Warren Olanow [Italie, États-Unis] | Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study |
000192 (2010) |
T. A. Zesiewicz [États-Unis] ; K. L. Sullivan [États-Unis] ; I. Arnulf [France] ; K. R. Chaudhuri [Royaume-Uni] ; J. C. Morgan [États-Unis] ; G. S. Gronseth [États-Unis] ; J. Miyasaki [Canada] ; D. J. Iverson [États-Unis] ; W. J. Weiner [États-Unis] | Practice Parameter: Treatment of nonmotor symptoms of Parkinson disease: Report of the Quality Standards Subcommittee of the American Academy of Neurology |
000194 (2010) |
Emmanuelle Pourcher [Canada, France] ; Sophie Remillard [Canada] ; Henri Cohen [Canada, France] | Compulsive habits in restless legs syndrome patients under dopaminergic treatment |
000208 (2009) |
S. Bourgault [Canada, France] ; D. Vaudry [France] ; A. Dejda [Canada, France] ; N. D. Doan [Canada, France] ; H. Vaudry [France] ; A. Fournier [Canada, France] | Pituitary Adenylate Cyclase-Activating Polypeptide: Focus on Structure-Activity Relationships of a Neuroprotective Peptide |
000223 (2008) |
C. Warren Olanow [États-Unis] ; Robert A. Hauser [États-Unis] ; Joseph Jankovic [États-Unis] ; William Langston [États-Unis] ; Anthony Lang [Canada] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Fabrizio Stocchi [Italie] ; Eldad Melamed [Israël] ; Eli Eyal [Israël] ; Olivier Rascol [France] | A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics |
000225 (2008) |
Anthony P. Nicholas [États-Unis] ; Farah D. Lubin [États-Unis] ; Penelope J. Hallett [États-Unis] ; Padmapriya Vattem [États-Unis] ; Paula Ravenscroft [Royaume-Uni] ; Erwan Bezard [France] ; SHAOBO ZHOU [Royaume-Uni] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] ; J. David Sweatt [États-Unis] ; David G. Standaert [États-Unis] | Striatal histone modifications in models of levodopa-induced dyskinesia |
000232 (2007) |
Robert A. Hauser [États-Unis] ; Olivier Rascol [France] ; Amos D. Korczyn [Israël] ; A. Jon Stoessl [Canada] ; Ray L. Watts [États-Unis] ; Werner Poewe [Autriche] ; Peter P. De Deyn [Belgique] ; Anthony E. Lang [Canada] | Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa |
000253 (2006) |
Naomi P. Visanji [Canada] ; Mark J. Millan [France] ; Jonathan M. Brotchie [Canada] | Actions at sites other than D3 receptors mediate the effects of BP897 on L-DOPA-induced hyperactivity in monoamine-depleted rats |
000263 (2004) |
C. Warren Olanow [États-Unis] ; Yves Agid [France] ; Yoshi Mizuno [Japon] ; Alberto Albanese [Italie] ; U. Bonucelli [Italie] ; Philip Damier [France] ; Justo De Yebenes [Espagne] ; Oscar Gershanik [Argentine] ; Mark Guttman [Canada] ; F. Grandas [Espagne] ; Mark Hallett [États-Unis] ; Ole Hornykiewicz [Autriche] ; Peter Jenner [Royaume-Uni] ; R. Katzenschlager [Royaume-Uni] ; William J. Langston [États-Unis] ; Peter Lewitt [États-Unis] ; Eldad Melamed [Israël] ; M. A. Mena [Espagne] ; P. P. Michel [France] ; Catherine Mytilineou [États-Unis] ; Jose A. Obeso [Espagne] ; Werner Poewe [Autriche] ; Niall Quinn [Royaume-Uni] ; R. Raisman-Vozari [France] ; Ali H. Rajput [Canada] ; Olivier Rascol [France] ; Christina Sampaio [Portugal] ; Fabrizio Stocchi [Italie] | Levodopa in the treatment of Parkinson's disease: Current controversies |
000268 (2004) |
M. A. Silverdale [Royaume-Uni] ; S. L. Nicholson [Royaume-Uni] ; P. Ravenscroft [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; M. J. Millan [France] ; J. M. Brotchie [Canada] | Selective blockade of D3 dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate |
000293 (2001) |
Olivier Rascol [France] ; Joaquim J. Ferreira [Portugal] ; Claire Thalamas [France] ; Monique Galitsky [France] ; Jean-Louis Montastruc [France] | Dopamine agonists: Their role in the management of Parkinson's disease |
000302 (2000) |
R. Kumar [Canada] ; A. E. Lang [Canada] ; M. C. Rodriguez-Oroz [Espagne] ; A. M. Lozano [Canada] ; P. Limousin [France] ; P. Pollak [France] ; A. L. Benabid [France] ; J. Guridi [Espagne] ; E. Ramos [Espagne] ; C. Van Der Linden [Belgique] ; A. Vandewalle [Belgique] ; J. Caemaert [Belgique] ; E. Lannoo [Belgique] ; D. Van Den Abbeele [Belgique] ; G. Vingerhoets [Belgique] ; M. Wolters [Belgique] ; J. A. Obeso [Espagne] | eep brain stimulation of the globus pallidus pars interna in advanced Parkinson's disease |
000304 (2000) |
M. Cyr [Canada] ; F. Calon [Canada] ; M. Morissette [Canada] ; M. Grandbois [Canada] ; S. Callier [Canada, France] ; T. Di Paolo [Canada] | Drugs with estrogen-like potency and brain activity : Potential therapeutic application for the CNS |
000305 (2000) |
O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; A. D. Korczyn [Israël] ; P. P. De Deyn [Belgique] ; C. E. Clarke [Royaume-Uni] ; A. E. Lang [Canada] | A five-year study of the incidence of dyskinesia in patients with early parkinson's disease who were treated with ropinirole or levodopa |
000315 (1999) |
M. A. Bedard [Canada] ; B. Pillon [France] ; B. Dubois [France] ; N. Duchesne [Canada] ; H. Masson [Canada] ; Yves Agid [France] | Acute and long-term administration of anticholinergics in Parkinson's disease : Specific effects on the subcortico-frontal syndrome |
000319 (1998) |
M.-A. Bedard [Canada] ; F. El Massioui [France] ; C. Malapani [France] ; B. Dubois [France] ; B. Pillon [France] ; B. Renault [France] ; Yves Agid [France] | Attentional deficits in Parkinson's disease : Partial reversibility with naphtoxazine (SDZ NVI-085), a selective noradrenergic α1 agonist |